Active, not recruitingPhase 1NCT05631899
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Studying Dendritic cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chinese PLA General Hospital
- Principal Investigator
- Yang Xu, Ph.D, MDZhejiang University
- Intervention
- KRAS-EphA-2-CAR-DC(biological)
- Enrollment
- 9 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing, Beijing Municipality, China
Collaborators
Zhejiang University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05631899 on ClinicalTrials.govOther trials for Dendritic cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07288112DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaDiakonos Oncology Corporation
- RECRUITINGPHASE1NCT07374029Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLDavid Avigan
- RECRUITINGPHASE1NCT06946615Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal CancerSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT06805305DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)Diakonos Oncology Corporation
- RECRUITINGPHASE1, PHASE2NCT06253494Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT05631886Combination of CAR-DC Vaccine and ICIs in Malignant TumorsChinese PLA General Hospital
- RECRUITINGPHASE1NCT05504707DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerH. Lee Moffitt Cancer Center and Research Institute
- ACTIVE NOT RECRUITINGPHASE1NCT05411497Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple MyelomaMayo Clinic